Shares of Intellia Therapeutics, Inc. (NTLA) have gained 14.9% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.08 indicates a potential upside of 408.6%.The mean estimate comprises 25 short-term price targets with a standard deviation of $26.66. While the lowest estimate of $9 indicates a 14.2% increase fro ...

Core Viewpoint - Enanta Pharmaceuticals (ENTA) has seen a 5.1% increase in share price over the past four weeks, closing at $5.18, with a mean price target of $15 indicating a potential upside of 189.6% according to Wall Street analysts [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $7.27, indicating variability among analysts; the lowest estimate suggests a 3.5% decline, while the highest predicts a 344% increase to $23 [2][9]. - Analysts' price targets are often viewed with skepticism due to historical inaccuracies, as they may not reliably indicate future stock price movements [7][10]. - A low standard deviation in price targets suggests a strong consensus among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising ENTA's earnings estimates upward, which correlates with potential stock price increases; the Zacks Consensus Estimate has risen by 26.2% over the past 30 days [4][12]. - ENTA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a solid potential upside [13].

Core Viewpoint - MoonLake Immunotherapeutics (MLTX) shows significant upside potential with a mean price target of $76.43, indicating a 106.6% increase from the current price of $36.99 [1] Price Targets and Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $13.12, suggesting variability among analysts [2] - The lowest estimate of $55 indicates a 48.7% increase, while the highest estimate predicts a surge of 181.2% to $104 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 1.7% over the past month, with two estimates going higher and no negative revisions [12] - MLTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of NovoCure (NVCR) have gained 8% over the past four weeks to close the last trading session at $17.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.14 indicates a potential upside of 105.5%.The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 57.9% increase from the current pric ...

QuinStreet (QNST) closed the last trading session at $15.88, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28.40 indicates a 78.8% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.90. While the lowest estimate of $19 indicates a 19.7% increase from the current price level, the most optimistic analyst expects ...

Core Insights - Amer Sports, Inc. is expected to report quarterly earnings of $0.15 per share, marking an 87.5% increase year-over-year, with revenues projected at $1.38 billion, reflecting a 16.5% year-over-year growth [1] Earnings Projections - Over the last 30 days, the consensus EPS estimate has been revised upward by 2.7%, indicating analysts' reassessment of their initial forecasts [2] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Estimates - Analysts forecast 'Segment Revenue- Technical Apparel' to reach $637.72 million, a year-over-year increase of 25% [5] - 'Segment Revenue- Outdoor Performance' is estimated at $453.74 million, reflecting a 13.4% year-over-year change [5] - 'Channel Revenues- DTC' is expected to be $626.77 million, indicating a 28.2% increase from the prior year [5] - 'Channel Revenues- Wholesale' is projected at $751.97 million, showing an 8.4% year-over-year change [6] - 'Segment Revenue- Ball & Racquet Sports' is anticipated to reach $287.29 million, a 5.2% increase year-over-year [6] - 'Geographic Revenues- Asia Pacific' is estimated at $152.72 million, reflecting a significant 46.8% year-over-year change [6] - 'Geographic Revenues- Greater China' is projected to be $399.35 million, indicating a 28.8% increase from the prior year [7] - 'Geographic Revenues- EMEA' is expected to reach $376.04 million, a 4.8% year-over-year change [7] - 'Geographic Revenues- Americas' is estimated at $440.88 million, reflecting a 7.5% year-over-year increase [7] Profit Estimates - 'Adjusted Operating Profit- Technical Apparel' is projected to be $146.17 million, compared to $117 million from the previous year [8] - 'Adjusted Operating Profit- Ball & Racquet Sports' is expected to reach $14.33 million, up from $11 million year-over-year [8] - 'Adjusted Operating Profit- Outdoor Performance' is anticipated at $27.12 million, compared to $19 million in the same quarter last year [9] Stock Performance - Over the past month, shares of Amer Sports, Inc. have returned +39.7%, significantly outperforming the Zacks S&P 500 composite's +9% change [10]

Wall Street analysts forecast that Toll Brothers (TOL) will report quarterly earnings of $2.86 per share in its upcoming release, pointing to a year-over-year decline of 15.4%. It is anticipated that revenues will amount to $2.5 billion, exhibiting a decline of 11.8% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to ...

Core Viewpoint - Huatai Securities has downgraded JD Logistics' profit forecast due to short-term cost increases outpacing revenue growth [1] Summary by Relevant Categories Financial Performance - The company has adjusted its profit margin assumptions for the year, leading to a 3% reduction in both net profit and non-IFRS profit forecasts [1] - The target price for JD Logistics has been lowered from HKD 17.8 to HKD 16.7, reflecting a target price-to-earnings ratio of 14.8 times [1] Investment Rating - Despite the adjustments, Huatai Securities maintains a "Buy" rating for JD Logistics [1]

Core Viewpoint - Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Cardiff Oncology suggest an improvement in the company's underlying business, potentially leading to higher stock prices [5]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Cardiff Oncology is expected to earn -$0.82 per share, reflecting a 13.7% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Cardiff Oncology has increased by 13.1%, indicating a positive trend in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Cardiff Oncology to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Viewpoint - COMPASS Pathways PLC has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for COMPASS Pathways for the fiscal year ending December 2025 is projected at -$1.82 per share, reflecting a 20.9% change from the previous year's reported figure [9]. - Over the past three months, the Zacks Consensus Estimate for COMPASS Pathways has increased by 13%, indicating a trend of rising earnings estimates [9]. Zacks Rating System - The Zacks rating system is based on changes in earnings estimates, which are crucial for determining stock price movements. It classifies stocks into five groups, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [2][10][11]. - The Zacks Rank 2 upgrade places COMPASS Pathways in the top 20% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term due to favorable earnings estimate revisions [11]. Market Impact - Rising earnings estimates and the corresponding rating upgrade for COMPASS Pathways suggest an improvement in the company's underlying business, which could lead to increased investor interest and a higher stock price [6]. - The influence of institutional investors, who adjust their valuations based on earnings estimates, contributes to the stock price movements, reinforcing the importance of earnings revisions [5].